Plasma pharmacokinetics, bioavailability, and tissue distribution in CD2F1 mice of halomon, an antitumor halogenated monoterpene isolated from the red algae Portieria hornemannii

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry, Environmental Science

• Identifiers
  DOI 10.1007/s002800050537PMID 8995499
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• O,p′-DDD (Mitotane) levels in plasma and tissues during chemotherapy and at autopsy

  2004cited by this paper
• Physiologically based pharmacokinetic models for anticancer drugs

  2004cited by this paper
• Plasma pharmacokinetics and urinary excretion of the polyamine analogue 1, 19-bis(ethylamino)-5, 10, 15-triazanonadecane in CD2F1 mice

  1996cited by this paper
• Isolation and structure/activity features of halomon-related antitumor monoterpenes from the red alga Portieria hornemannii.

  1994cited by this paper
• A pentahalogenated monoterpene from the red alga Portieria hornemannii produces a novel cytotoxicity profile against a diverse panel of human tumor cell lines.

  1992cited by this paper
• Oxidative and reductive metabolism by cytochrome P450 2E1

  1992cited by this paper
• Data Display and Analysis Strategies for the NCI Disease-Oriented in Vitro Antitumor Drug Screen

  1992cited by this paper
• Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies

  1991cited by this paper
• Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects.

  1991cited by this paper
• Pharmacologically guided phase I clinical trials based upon preclinical drug development.

  1990cited by this paper
• Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm.

  1989cited by this paper
• Man versus beast: pharmacokinetic scaling in mammals.

  1986cited by this paper
• Dosage regimen design for pharmaceutical studies conducted in animals.

  1986cited by this paper
• Potential roles for preclinical pharmacology in phase I clinical trials.

  1986cited by this paper
• An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of methodologies

  1986cited by this paper
• Pharmacokinetic scale-up: accurate prediction of human pharmacokinetic profiles from animal data.

  1985cited by this paper
• LAGRAN program for area and moments in pharmacokinetic analysis.

  1983cited by this paper
• A program package for simulation and parameter estimation in pharmacokinetic systems.

  1979cited by this paper
• A Bayesian extension of the minimum AIC procedure of autoregressive model fitting

  1979influential reference
• A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation

  1978cited by this paper
• Chemical constituents of the digestive gland of the sea hare Aplysia californica. I. Importance of diet.

  1974cited by this paper
• Applications of a Mathematical Model for Drug Distribution in Mammals

  1967cited by this paper

• Profiling of Volatile Organic Compounds, Including Halogenated Substances, in Okinawan Red Alga Portieria hornemannii

  2025cites this paper
• Marine Algae and Deriving Biomolecules for the Management of Inflammatory Bowel Diseases: Potential Clinical Therapeutics to Decrease Gut Inflammatory and Oxidative Stress Markers?

  2024influential citation
• Anti-Inflammatory Halogenated Monoterpenes from the Red Alga Portieria hornemannii

  2023cites this paper
• Pharmacokinetics of Marine-Derived Drugs

  2020influential citation
• Molecular genomic features associated with in vitro response of the NCI‐60 cancer cell line panel to natural products

  2020cites this paper
• Plants That Fight Cancer

  2019cites this paper
• Seaweed Secondary Metabolites with Beneficial Health Effects: An Overview of Successes in In Vivo Studies and Clinical Trials

  2019cites this paper
• A Novel Polyhalogenated Monoterpene Induces Cell Cycle Arrest and Apoptosis in Breast Cancer Cells

  2019cites this paper
• Ultra‐high resolution band‐selective HSQC for nanomole‐scale identification of chlorine‐substituted 13C in natural products drug discovery

  2017cites this paper
• Tribenzyltin carboxylates as anticancer drug candidates: Effect on the cytotoxicity, motility and invasiveness of breast cancer cell lines.

  2017cites this paper
• Highly Selective Synthesis of Halomon, Plocamenone, and Isoplocamenone.

  2015cites this paper
• Studies towards the synthesis of halomon: asymmetric hexafunctionalisation of myrcene.

  2014cites this paper
• Rhodophyceae (Red Algae)

  2014cites this paper
• Terpenes transfer to milk and cheese after oral administration to sheep fed indoors.

  2012cites this paper
• Assessment of in vitro antitumoral and antimicrobial activities of marine algae harvested from the eastern Mediterranean sea

  2010cites this paper
• Natural Products from Seaweeds

  2009cites this paper
• DNA methyl transferase inhibiting halogenated monoterpenes from the Madagascar red marine alga Portieria hornemannii.

  2006cites this paper
• Chemical investigation of predator-deterred macroalgae from the Antarctic peninsula.

  2004cites this paper
• Screening marine algae from China for their antitumor activities

  2004cites this paper
• USEFUL PRODUCTS FROM ALGAL PHOTOSYNTHESIS

  2004cites this paper
• Bioactive natural products from marine sources

  2001cites this paper
• Transfer of monoterpenes and sesquiterpenes from forages into milk fat

  2000cites this paper
• Synthesis of Several Naturally Occurring Polyhalogenated Monoterpenes of the Halomon Class(1).

  1997cites this paper
• In vitro metabolism by mouse and human liver preparations of halomon, an antitumor halogenated monoterpene

  1997cites this paper